APOLO Biotech

APOLO Biotech is a pioneering agri-biotechnology company developing next-generation RNA-based solutions to transform crop protection and crop modulation. Founded in Argentina and now expanding globally, APOLO is building a platform to deliver safe, sustainable, and highly effective alternatives to chemical pesticides and fertilizers, addressing some of the most pressing challenges in agriculture today.
 

Our core technology leverages double-stranded RNA (dsRNA) to specifically silence the expression of target genes in pathogens or in plants, enabling two strategic applications:

1. Fungal pathogen control – developing RNA molecules that combat major fungal diseases where chemical control is ineffective, restricted, or facing resistance.
2. Crop modulation – designing RNA triggers that help plants better tolerate abiotic stresses such as drought and heat shocks, or enhance traits like root nodulation and productivity.
    

Over the last three years, APOLO has achieved remarkable milestones:

• Conducted more than 50 field trials across Latin America and Europe, validating RNA-based solutions in real-world agricultural conditions.
• Built the first RNA pilot production plant in Latin America, reducing production costs by over 99%, and making RNA technology affordable and scalable for farmers.
   
• Advanced a robust product pipeline, with pre-commercial agreements already signed with key industry players. To date, APOLO has secured over USD 900K in pre-commercial commitments, and is in advanced negotiations with global partners.
   
• Recognized internationally, APOLO was awarded by EIT Food Accelerator Network (FAN), securing both investment and strategic support to expand operations in Europe.
   

APOLO is now entering a new growth phase with three key priorities:

1. Regulatory approvals – targeting the first RNA-based product registration in Latin America by 2026, a milestone that would represent the world’s first registered RNA solution for fungal pathogens.
2. Global expansion – setting up laboratories and the first RNA pilot plant in Europe at Paris-Saclay, in collaboration with Dr. Martin Crespi, to support European R&D and supply. The company also plans to establish future facilities in strategic markets such as the Middle East.
3. Innovation pipeline – expanding collaborations with corporate partners to develop customized RNA solutions, including exclusive projects for crops such as vanilla, cacao, citrus, and banana, as well as solutions to replace chemicals in diseases like Botrytis, Fusarium, and Sclerotinia.

Our business model combines:

• Product commercialization through strategic distributors under a “powered by APOLO Biotech” brand, leveraging established market channels.
• Collaborative R&D projects (24–36 months) with milestone-based payments, tailored to solve specific problems not yet covered in our portfolio.
• Licensing opportunities for partners seeking exclusive solutions for high-value crops and markets.
   

APOLO Biotech is currently raising USD 3.5–5M. This round will allow us to:

• - Register our first product in LATAM.
• - Build our European R&D hub and RNA pilot plant in Paris-Saclay.
• - Submit our first patent.
• - Expand our product pipeline in partnership with leading global agribusinesses.

With operations in Argentina, France, and soon in new geographies, APOLO Biotech is positioning itself as a global leader in agricultural RNA technology, driving the transition toward chemical-free, climate-resilient farming and shaping the future of sustainable food production.